Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
16.31
+0.25 (1.56%)
At close: Jul 21, 2025, 4:00 PM
16.35
+0.04 (0.25%)
After-hours: Jul 21, 2025, 7:57 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
The 7 analysts that cover Teva Pharmaceutical stock have a consensus rating of "Strong Buy" and an average price target of $24.71, which forecasts a 51.5% increase in the stock price over the next year. The lowest target is $22 and the highest is $30.
Price Target: $24.71 (+51.5%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 5 | 4 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 2 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 6 | 6 | 7 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $24 → $23 | Strong Buy | Maintains | $24 → $23 | +41.02% | Jun 26, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +47.15% | Jun 6, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +53.28% | May 28, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $21 → $23 | Hold → Buy | Upgrades | $21 → $23 | +41.02% | May 12, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $20 → $22 | Strong Buy | Maintains | $20 → $22 | +34.89% | May 8, 2025 |
Financial Forecast
Revenue This Year
17.49B
from 16.54B
Increased by 5.69%
Revenue Next Year
17.49B
from 17.49B
EPS This Year
2.60
from -1.45
EPS Next Year
2.67
from 2.60
Increased by 2.52%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 18.2B | 18.3B | 18.9B |
| Avg | 17.5B | 17.5B | 17.8B |
| Low | 16.6B | 16.6B | 16.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.2% | 4.7% | 8.1% |
| Avg | 5.7% | - | 2.1% |
| Low | 0.4% | -5.2% | -6.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.71 | 2.92 | 3.31 |
| Avg | 2.60 | 2.67 | 2.97 |
| Low | 2.45 | 2.45 | 2.71 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 12.1% | 24.1% |
| Avg | - | 2.5% | 11.3% |
| Low | - | -5.9% | 1.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.